ライフサイエンスコーパス: hemagglutinin

1 genically distinct, influenza glycoproteins (hemagglutinins).

2 conserved stalk domain of influenza B virus hemagglutinin.

3 shared with the 2009 pandemic H1N1 (Cal/04) hemagglutinin.

4 utralizing antibodies target influenza virus hemagglutinin.

5 taneously inducing high levels of Abs toward hemagglutinin.

6 anes of fibroblast cells that stably express hemagglutinin.

7 onserved stalk domain of the influenza virus hemagglutinin.

8 tralizing humoral immunity against the viral hemagglutinin.

9 tralizing humoral immunity against the viral hemagglutinin.

10 n of potent peptidic inhibitors of influenza hemagglutinin.

11 H5N8 (H5Nx) viruses containing the Eurasian hemagglutinin 2.3.4.4 clade from wild bird populations i

12 ric assessment of binding thermodynamics for hemagglutinin 306-319 peptide variants to the human MHC

13 shown to describe fusion by influenza virus hemagglutinin (a "class I" fusogen) and West Nile virus

14 In hemagglutinin, a small set of mutations arises independe

15 s found to utilize a relatively lower pH for hemagglutinin activation, similar to human influenza vir

16 ttering experimental data of the filamentous hemagglutinin adhesin beta-barrel protein transporter so

17 reater Fc receptor activity to pandemic H1N1 hemagglutinin after the swine influenza pandemic of 2009

18 ly neutralizing antibodies against influenza hemagglutinin and HIV Env.

19 image the distributions of antibody-labeled hemagglutinin and isotope-labeled cholesterol and sphing

20 controlled by cohesive interactions between hemagglutinin and liquid-ordered domains enriched with c

21 Hemagglutinin and MOG are both presented to T cells, whi

22 Both hemagglutinin and neuraminidase activities of viruses be

23 assortments of H5 and H6N6 viruses, with the hemagglutinin and neuraminidase combinations being stron

24 ained with recombinant proteins for both the hemagglutinin and neuraminidase indicate a true avian re

25 luated if a reassortant virus containing the hemagglutinin and neuraminidase of A/quail/Hong Kong/G1/

26 rly, antibody titers against influenza virus hemagglutinin and neuraminidase significantly decreased

27 ntibodies to the viral surface glycoproteins hemagglutinin and neuraminidase, and these responses can

28 a and IL-17-producing cells specific for the hemagglutinin and nucleocapsid proteins appeared in circ

29 nonsynonymous genetic diversity in the viral hemagglutinin and nucleoprotein, and (iii) intrahost vir

30 phtheria toxin, pertussis toxin, filamentous hemagglutinin and pertactin were measured at 14 and 24 w

31 ort physiologically relevant binding of H3N2 hemagglutinin and that this physiologically relevant bin

32 ly targeted the conserved stalk region of H1 hemagglutinin and was effective against drug-resistant H

33 titutes a novel method of escape for group 1 hemagglutinins and could represent an alternative means

34 to pertussis toxin, antibody to filamentous hemagglutinin, and antibody to pertactin were measured i

35 closely across all groups, against all 3 TIV hemagglutinins, and in all ADCC assays tested.

36 In influenza, broadly neutralizing anti-hemagglutinin (anti-HA) stalk mAbs require Fc-FcgammaR i

37 and alpha-GalCer induced high titers of anti-hemagglutinin antibodies and generated virus-specific T

38 was defined as >/=4-fold increase in paired hemagglutinin antibody inhibition titers from 1 month po

39 ertussis toxin (anti-PT) or anti-filamentous hemagglutinin antibody titers, and by genetic testing (p

40 nt adjuvants for recombinant influenza virus hemagglutinin antigen induction of humoral and cellular

41 unization with this adjuvant and recombinant hemagglutinin antigen is transferable with serum from im

42 Mapping the H7 hemagglutinin antigenic sites by generating escape mutan

43 red influenza vaccines that express chimeric hemagglutinin antigens offer a novel means for protectin

44 Mannose-resistant Klebsiella-like (Mrk) hemagglutinins are critical for K pneumonia biofilm deve

45 We tested this hypothesis using influenza hemagglutinin as a model viral antigen and transgenic, M

46 N2v have acquired antigenic mutations in the hemagglutinin at amino acid position 145 (N145K/R).

47 The present data suggest that chimeric hemagglutinin-based vaccination is a viable strategy to

48 which we named "urumin," is virucidal for H1 hemagglutinin-bearing human influenza A viruses.

49 l antibody against conserved epitopes of the hemagglutinin can be combined with TIV to elicit broad p

50 Vaccination with a divergent hemagglutinin can thus increase the frequency of B cells

51 l of influenza A viruses expressing chimeric hemagglutinins (cHA) with intragroup or intergroup head/

52 r from specific binding interactions between hemagglutinin, cholesterol, and/or the majority of sphin

53 Six hemagglutinin clades and 8 genotypes were identified in

54 d flock, where we identified haplotypes with hemagglutinin cleavage site of different lengths.

55 strains showing a different insertion at the hemagglutinin cleavage site, as well as nine nucleotide

56 Thus, hemagglutinin clustering and localization in the plasma

57 We found that the hemagglutinin clusters were neither enriched with choles

58 otective vaccine candidate based on chimeric hemagglutinins, consisting of globular head domains from

59 NK cells by human IgG-opsonized influenza A hemagglutinin correlated with dimeric rsFcgammaRIIIa bin

60 known antibodies with binding affinity to H7 hemagglutinin could be identified from survivors.

61 ime-boost influenza vaccine trial, we sorted hemagglutinin cross-reactive memory B cells and identifi

62 Insertion of a 9-residue hemagglutinin epitope in IS1S2, but not in IS5S6 or in I

63 Molecular modeling of the hemagglutinin esterase fusion protein of D/3-13 identifi

64 nerally agreed with the surface glycoprotein hemagglutinin esterase phylogeny, were observed between

65 equires the interplay of the virion-attached hemagglutinin-esterase and fusion glycoproteins.

66 Importantly, ISAV hemagglutinin-esterase receptor engagement does not init

67 e, we present the crystal structures of ISAV hemagglutinin-esterase unbound and complexed with recept

68 t is dependent on the oligomeric assembly of hemagglutinin-esterase.

69 Hemagglutinin-esterases (HEs) are bimodular envelope pro

70 generate Abs capable of neutralizing variant hemagglutinin-expressing pseudotyped lentiviruses.

71 e fusion assay, using transfected fusion and hemagglutinin expression plasmids or with syncytium-base

72 mbinant pertussis toxin (PT) and filamentous hemagglutinin (FHA) were assessed by enzyme-linked immun

73 es against pertussis toxin (PT), filamentous hemagglutinin (FHA), pertactin (Prn), tetanus toxoid (TT

74 broadly neutralizing antibodies against the hemagglutinin (FI6v3 and CR9114).

75 protein and to match the trimeric nature of hemagglutinin for improved avidity.

76 than twofold increase in the affinity of its hemagglutinin for mammalian receptors: the model predict

77 nfection or vaccination with VLPs containing hemagglutinin from A/PR8/34 influenza virus induced high

78 s and glycan microarray data for recombinant hemagglutinins from A(H6N1) and A(H10N8) viruses, isolat

79 , and that immunization with influenza virus hemagglutinin fused to hXCL1 or hXCL2 induced full prote

80 V interacts with STING through its conserved hemagglutinin fusion peptide (FP).

81 in can be substituted by the influenza virus hemagglutinin fusion peptide, and this chimera also acti

82 that membrane remodeling commenced with the hemagglutinin fusion protein spikes grappling onto the t

83 Six hemagglutinin gene clades were characterized.

84 The first approach was to modify the hemagglutinin gene of a highly pathogenic wild-type (wt)

85 The hemagglutinin gene of these H7 viruses are separated fro

86 an H7N9 formulation containing 15 microg of hemagglutinin given without adjuvant, with AS03 adjuvant

87 jor antigenic sites in the influenza A virus hemagglutinin globular domain.

88 en accompanied by glycan accumulation on the hemagglutinin globular head, and hemagglutinin receptor

89 We evaluated the effect of hemagglutinin glycosylation on receptor binding and viru

90 MR, 0.89; 95% CI, 0.87-0.90) and filamentous hemagglutinin (GMR, 0.89; 95% CI, 0.88-0.90) and 22% low

91 target cells by coordinated action of the MV hemagglutinin (H) and fusion (F) envelope glycoproteins;

92 The hemagglutinin (H) gene and hypervariable region between

93 to determine the glycosylation of Influenza hemagglutinin (H1/A/California/04/2009) using the follow

94 Hemagglutinin H7 administered alone is a poor immunogen

95 Changes in hemagglutinin (HA) acquired by contemporary A(H3N2) viru

96 bulin (Ig) 2D1 is effective against the 1918 hemagglutinin (HA) and also known to cross-neutralize th

97 epitope in the vestigial esterase domain of hemagglutinin (HA) and blocks HA-mediated membrane fusio

98 Viral glycoproteins, such as influenza hemagglutinin (HA) and human immunodeficiency virus gp41

99 urally defined interaction between influenza hemagglutinin (HA) and its cell surface receptor sialic

100 by reverse genetics using the wild-type (wt) hemagglutinin (HA) and neuraminidase (NA) genes from the

101 Genetic analysis of the hemagglutinin (HA) and neuraminidase (NA) genes of this

102 ions of the influenza virus surface proteins hemagglutinin (HA) and neuraminidase (NA) is thought to

103 Antibody titers to influenza hemagglutinin (HA) and neuraminidase (NA) surface antige

104 the interaction of the surface glycoproteins hemagglutinin (HA) and neuraminidase (NA) with the cell

105 e is controlled by the surface glycoproteins hemagglutinin (HA) and neuraminidase (NA).

106 ible among mammals by acquiring mutations in hemagglutinin (HA) and polymerase.

107 monoclonal antibody, m826, that binds to H7 hemagglutinin (HA) and protects against H7N9 infection.

108 ltivalent interactions between virus surface hemagglutinin (HA) and sialoside-containing glyco ligand

109 The hemagglutinin (HA) antibody epitope repertoires of 15 H7

110 f-amplifying mRNA expressing influenza virus hemagglutinin (HA) antigen [SAM(HA)] formulated with a n

111 f computationally optimized broadly reactive hemagglutinin (HA) antigens (COBRA) for H1N1 isolates.

112 We generated mice expressing the hemagglutinin (HA) as a "neo-self-antigen" specifically

113 dity trimeric proteins that bind influenza A hemagglutinin (HA) at its conserved receptor binding sit

114 7/8 agonist 3M-052, in combination with H5N1 hemagglutinin (HA) based antigens.

115 Changes in hemagglutinin (HA) binding and NA specificity in reassor

116 Cleavage of influenza virus hemagglutinin (HA) by host cell proteases is necessary f

117 kers and their predicted phenotypic effects, hemagglutinin (HA) clade classifications, an automated t

118 plasmic tail of influenza virus glycoprotein hemagglutinin (HA) contains three cysteines, posttransla

119 Residues in the RBS of influenza virus hemagglutinin (HA) determine a preference for the avian

120 The influenza virus hemagglutinin (HA) envelope protein mediates virus entry

121 Previously, a novel hemagglutinin (HA) for H5N1 influenza was derived from a

122 irus vaccines rely on the antigenic match of hemagglutinin (HA) for vaccine strain selection, and mos

123 ibodies against tetanus toxoid and influenza hemagglutinin (HA) from H1N1 and newly emergent subtypes

124 y against influenza viruses by targeting the hemagglutinin (HA) fusion machinery.

125 f adenovirus serotype 6 (Ad6) to express the hemagglutinin (HA) gene from influenza A/PR/8/34 virus.

126 as used to determine genetic group, based on hemagglutinin (HA) gene sequences, of influenza A(H3N2)

127 For influenza virus, the trimeric hemagglutinin (HA) glycoprotein spike mediates host cell

128 iruses continuously acquire mutations in the hemagglutinin (HA) glycoprotein that abrogate binding of

129 primarily focused on the head region of the hemagglutinin (HA) glycoprotein, which in turn undergoes

130 mune responses to influenza virus target the hemagglutinin (HA) glycoprotein, which is the major anti

131 o cell surface sialic acid receptors via the hemagglutinin (HA) glycoprotein, with the neuraminidase

132 When hemagglutinin (HA) glycoproteins from influenza A virus

133 The majority of these antibodies bind to the hemagglutinin (HA) head domain and function by blocking

134 Influenza A virus hemagglutinin (HA) initiates viral entry by engaging hos

135 The influenza virus hemagglutinin (HA) is a major target of the humoral immu

136 Influenza virus hemagglutinin (HA) is responsible for binding to host ce

137 antibodies against the surface glycoprotein hemagglutinin (HA) is the primary method used to control

138 Two antigenically distinct IBV hemagglutinin (HA) lineages cocirculate worldwide with l

139 A similar defect in intronless hemagglutinin (HA) mRNA nuclear export was seen with an

140 antibodies to the 'stem' of influenza virus hemagglutinin (HA) now allow us to incorporate into simu

141 Hemagglutinin (HA) of influenza virus must be activated

142 8-like avian virus) carrying either the 1918 hemagglutinin (HA) or PB2 gene.

143 L chain usage of the Ab response against the hemagglutinin (HA) protein elicited by influenza infecti

144 Key mutations in the virus hemagglutinin (HA) protein or reassortment with other pa

145 Meanwhile, influenza hemagglutinin (HA) protein sequences are also effective

146 t a single amino acid at position 158 of the hemagglutinin (HA) protein substantially affected the sy

147 umulation of amino acid substitutions in the hemagglutinin (HA) protein, resulting in escape from pri

148 y, where virions with relatively acid-stable hemagglutinin (HA) proteins are rendered incapable of pH

149 First, we tested the binding of recombinant hemagglutinin (HA) proteins of seal H3N8 and human-adapt

150 a between 2005 and 2015, particularly at the hemagglutinin (HA) proteolytic cleavage site (PCS) that

151 lates, have a leucine at position 226 in the hemagglutinin (HA) receptor binding site, which is criti

152 rimentally introduced mutations in the viral hemagglutinin (HA) receptor-binding domain conferred bin

153 tions to ablate m(6)A on both strands of the hemagglutinin (HA) segment.

154 he above approach to analyze influenza viral hemagglutinin (HA) sequences.

155 ected against the stalk domains of the viral hemagglutinin (HA) show promise for protecting against d

156 man monoclonal antibody (hMAb) targeting the hemagglutinin (HA) stalk offers a promising approach to

157 reactive antibodies targeting the conserved hemagglutinin (HA) stalk region are elicited following s

158 Here, we demonstrate that the hemagglutinin (HA) stalk-targeting human monoclonal anti

159 The hemagglutinin (HA) stem is a promising target for univer

160 eutralizing antibodies (bnAbs) targeting the hemagglutinin (HA) stem revitalized hopes of developing

161 ing human antibodies targeting the influenza hemagglutinin (HA) stem, with exceptional neutralizing b

162 Avian influenza viruses of the H7 hemagglutinin (HA) subtype present a significant public

163 protection against severe disease from novel hemagglutinin (HA) subtypes in the same phylogenetic gro

164 embers of a subgroup (H7-H10-H15) of group 2 hemagglutinin (HA) subtypes that include H7N9 and H10N8

165 2, effectively reacting with all influenza A hemagglutinin (HA) subtypes.

166 e fusion mediated by the H1 and H5 (group 1) hemagglutinin (HA) subtypes.

167 pandemics require that a virus containing a hemagglutinin (HA) surface antigen previously unseen by

168 ting specific antibody responses against the hemagglutinin (HA) surface glycoprotein; however, the di

169 E1) and chNHE1 and by ECL replacement with a hemagglutinin (HA) tag.

170 antigenic site B of the surface glycoprotein hemagglutinin (HA) that explain the antigenic difference

171 ve antigens (COBRA) was used to design novel hemagglutinin (HA) vaccine immunogens.

172 ere that an arginine to lysine change in the hemagglutinin (HA) was also necessary.

173 ic analysis identified T-cell epitopes in H7 hemagglutinin (HA) which potentially enhance regulatory

174 Hemagglutinin (HA), a glycoprotein abundant on the virio

175 rgely determined by the surface glycoprotein hemagglutinin (HA), and amino acid substitutions at expo

176 trated here for antibodies against HIV1-p17, hemagglutinin (HA), and dengue virus type I.

177 ion T401A occurred prior to substitutions in hemagglutinin (HA), causing the altered receptor-binding

178 hat glycosylation of influenza A virus (IAV) hemagglutinin (HA), especially at position N-27, is cruc

179 Each focuses ~80% of the response on hemagglutinin (HA), mainly through recognition of the ma

180 Some proteins, like hemagglutinin (HA), NA, and M2, are integral membrane pr

181 viruses of mice that had been immunized with hemagglutinin (HA), neuraminidase (NA) and the extracell

182 st H7N9 virus-infected cells and recombinant hemagglutinin (HA), neuraminidase (NA), and nucleoprotei

183 r example, in the influenza envelope protein hemagglutinin (HA), the low pH in the endosome triggers

184 terations in the viral surface glycoprotein, hemagglutinin (HA), typically are required for influenza

185 ing reverse genetics and fixing the CIV-H3N2 hemagglutinin (HA), we found that 51 of the 127 possible

186 fic mAbs target the head domain of the viral hemagglutinin (HA), whereas broadly reactive mAbs typica

187 examine the influenza A virus spike protein hemagglutinin (HA), which undergoes a dynamic conformati

188 sights into the mechanisms by which chimeric hemagglutinin (HA)-based vaccines confer immunity, namel

189 ly replicate in murine macrophages through a hemagglutinin (HA)-mediated mechanism.

190 tudies demonstrated that these classes block hemagglutinin (HA)-mediated membrane fusion.

191 measured by a microneutralization assay, and hemagglutinin (HA)-specific and nucleoprotein (NP)-speci

192 Longitudinal tracking of vaccination-induced hemagglutinin (HA)-specific clones revealed no overall i

193 recognizing conserved surfaces on the viral hemagglutinin (HA).

194 genic changes in the viral envelope protein, hemagglutinin (HA).

195 rus based on the sequence of surface protein hemagglutinin (HA).

196 ies targeting the globular head of the viral hemagglutinin (HA).

197 tutions in the major influenza virus antigen hemagglutinin (HA).

198 IBV are distinguished, based on variation in hemagglutinin (HA): B/Victoria/2/87-like (B/Vic) and B/Y

199 determining the structure of influenza-virus hemagglutinin (HA):single-chain variable-domain fragment

200 Using pseudoviruses bearing various hemagglutinins (HA-pseudoviruses), we found serum neutra

201 icenter trial of RIV4 (45 mug of recombinant hemagglutinin [HA] per strain, 180 mug of protein per do

202 mplifies the most critical genomic segments (hemagglutinin [HA], neuraminidase [NA], and matrix [M])

203 1N1]pdm09) and avian influenza A(H7N9) virus hemagglutinins (HAs) despite being seronegative for thes

204 -reactive antibodies showed broad binding to hemagglutinins (HAs) from previously circulating virus s

205 of the subgroup of influenza A virus group 2 hemagglutinins (HAs) that also include H7 and H10.

206 ntaining wild-type and mutant MN/10 or BJ/92 hemagglutinins (HAs) were constructed and probed for rea

207 Receptor-binding preference and stability of hemagglutinin have been implicated as crucial determinan

208 : fusion protein (F) and attachment proteins hemagglutinin, hemagglutinin-neuraminidase, or glycoprot

209 Construction of an IE3-hemagglutinin (IE3-HA) virus by insertion of an in-frame

210 The adjuvants boosted anti-hemagglutinin IgG and IgA antibody levels.

211 responses to tetanus toxin but not influenza hemagglutinin in the ART group were lower than those in

212 s anthracis protective antigen and influenza hemagglutinin-in which B cells competed both intra- and

213 across nine different amino acid residues in hemagglutinin including seven that have not been describ

214 ent adjuvant for recombinant influenza virus hemagglutinin, inducing rapid and sustained immunity tha

215 ibition of adhesion: the model predicts that hemagglutinin inhibitors of relatively modest affinity c

216 We therefore speculate that local sterol-hemagglutinin interactions in the viral envelope may con

217 Influenza hemagglutinin is a surface glycoprotein related to virus

218 When influenza hemagglutinin is also present in the membrane of the tar

219 le amino acid residue substitution in NY1682 hemagglutinin is responsible for the difference in infec

220 the antigenic epitopes of the major antigen, hemagglutinin, is required.

221 essed an antigenically important mutation in hemagglutinin (K166Q).

222 ecipient mice after the cocapture of MOG and hemagglutinin leads to the production of class-switched

223 When applied to the adhesion between the hemagglutinin ligands on influenza viruses and the siali

224 esicular stomatitis virus (VSV) encoding the hemagglutinin-like envelope glycoproteins HL17 or HL18 i

225 agment of an antibody that blocks the normal hemagglutinin-mediated mode of viral attachment.

226 The measles virus hemagglutinin (MeV-H) protein is the main target of prot

227 e 11th gene of the 16-gene mannose-sensitive hemagglutinin (MSHA) type IV pilus operon), had reduced

228 glycoproteins: an attachment protein called hemagglutinin-neuraminidase (HN [also called H or G depe

229 the sequences of the Small Hydrophobic (SH), Hemagglutinin-Neuraminidase (HN) and Fusion (F) genes of

230 ajor attachment glycoprotein (G) between the hemagglutinin-neuraminidase (HN) and RNA-dependent RNA p

231 eign gene at the PIV5 small hydrophobic (SH)-hemagglutinin-neuraminidase (HN) junction or deletion of

232 wo mutations, one each in the fusion (F) and hemagglutinin-neuraminidase (HN) proteins.

233 ated action of the receptor-binding protein, hemagglutinin-neuraminidase (HN), and the fusion protein

234 cleavage site, F117S (F117S), and another in hemagglutinin-neuraminidase (HN), G169R (HN169R), locate

235 orchestrated by the receptor binding protein hemagglutinin-neuraminidase (HN; also called H or G depe

236 teins: the attachment glycoprotein (G, H, or hemagglutinin-neuraminidase [HN]) and the fusion glycopr

237 n (F) and attachment proteins hemagglutinin, hemagglutinin-neuraminidase, or glycoprotein (G), which

238 onstructed mutants with substitutions in the hemagglutinin of A/Netherlands/602/09 in an attenuated b

239 amino acid substitutions was observed in the hemagglutinin of H7 AIVs from waterfowl and domestic pou

240 Thus, the hemagglutinin of the A/H7N9 virus may adopt traits assoc

241 mmunization with an immunologically distinct hemagglutinin of the same subtype offers the potential t

242 an infections in 2013, and compare them with hemagglutinins of avian origin.

243 g to quadrivalent formulations including the hemagglutinins of influenza A subtypes H1N1 and H3N2 and

244 inin trimers, so the spatial distribution of hemagglutinin on the viral envelope may influence fusion

245 y later than particles bearing the influenza hemagglutinin or GP from lymphocytic choriomeningitis vi

246 o the RepRNA (luciferase, or influenza virus hemagglutinin or nucleoprotein) could decrease, while th

247 (hemagglutinin receptor binding specificity, hemagglutinin pH of activation, and polymerase complex e

248 s mutations to reproduce influenza's spindly hemagglutinin phylogeny, co-circulation of antigenic var

249 Cleavage of the hemagglutinin precursor by host proteases is a critical

250 C-Ads generate markedly more influenza virus hemagglutinin protein and require substantially less vec

251 the conserved receptor-binding pocket of the hemagglutinin protein and to match the trimeric nature o

252 Amino acid substitutions in the hemagglutinin protein can result in escape from neutrali

253 The hemagglutinin protein of the isolated virus and virus se

254 The inhibitors did not block hemagglutinin protein-mediated binding to the target cel

255 utations at key antigenic sites of the viral hemagglutinin protein.

256 dies that interfere with the function of the hemagglutinin protein.

257 paper-based influenza assay that targets the hemagglutinin protein; the assay employs a combination o

258 omplexity and leveraging the large number of hemagglutinin proteins on the surface of each virus.

259 tion on the hemagglutinin globular head, and hemagglutinin receptor binding has changed from recognit

260 ts contained amino acid deletions within the hemagglutinin receptor binding site.

261 three specific traits of influenza viruses (hemagglutinin receptor binding specificity, hemagglutini

262 actors essential for processing of the virus hemagglutinin represent very suitable drug targets becau

263 Co-crystal structures with hemagglutinin revealed that each class utilized characte

264 tructure and receptor specificity of the H15 hemagglutinin, revealing distinct features and specifici

265 crease in ADCC-Ab titers to both recombinant hemagglutinin (rHA) protein and homologous virus-infecte

266 VA peptide, and the alpha-helix of influenza hemagglutinin's stem; the last afforded protection again

267 this approach, 100% sequence coverage of the hemagglutinin sample was obtained.

268 Based on the IAV hemagglutinin, seven different influenza A viral groups

269 tative estimate of the affinity range of the hemagglutinin-sialic acid interaction necessary for the

270 t pandemic H1N1 influenza virus in which the hemagglutinin signal sequence has been suppressed (S-FLU

271 urther find that sterol-dependent changes to hemagglutinin spatial patterning in the viral membrane d

272 arrow-derived radioresistant cells to induce hemagglutinin-specific antibodies and protect mice again

273 lacked robust clonal expansion of influenza hemagglutinin-specific B cells early after infection and

274 sequence, MOG-specific B cells get help from hemagglutinin-specific T cells to produce anti-MOG antib

275 MOG antibodies, dependent on the presence of hemagglutinin-specific T cells.

276 d virus-neutralizing antibody titers but not hemagglutinin stalk antibody titers were lower in proges

277 uenza virucide that specifically targets the hemagglutinin stalk region, similar to targeting of anti

278 arget membrane dimpling as local clusters of hemagglutinin started to undergo conformational refoldin

279 The hemagglutinin stem binding bNAbs CR6261 and CR9114 have

280 antibodies (HV1-69-sBnAb) to the influenza A hemagglutinin stem domain has been clearly established.

281 ifs to recognize overlapping epitopes in the hemagglutinin stem.

282 y, using the small nine amino acid influenza hemagglutinin tag.

283 Here we developed a Flag- and hemagglutinin-tagged Fancd2 knock-in mouse strain that a

284 tigenic cartography of all H3N2 viruses with hemagglutinin (the glycoprotein on the surface of the in

285 ds (S3-G4) showed the strongest binding to a hemagglutinin trimer (dissociation constant of 1.6 x 10(

286 s at near-atomic resolution of the influenza hemagglutinin trimer, which adopts a highly preferred sp

287 aneously binding to two subunits of a single hemagglutinin trimer.

288 at fusion requires the engagement of several hemagglutinin trimers in close proximity.

289 Optimal fusion likely requires multiple hemagglutinin trimers, so the spatial distribution of he

290 for a homologue of the temperature-sensitive hemagglutinin (Tsh) autotransporter described in avian E

291 Among those, a mutation in the viral hemagglutinin was identified that increases 2009 pandemi

292 e antigens cytomegalovirus pp65 or influenza hemagglutinin were able to present the antigens to autol

293 an array binding features of the recombinant hemagglutinin were determined.

294 lls and memory B cells specific to influenza hemagglutinin were primarily observed in the mediastinal

295 clustering or spatial rearrangement of viral hemagglutinin, which affects the rate-limiting step of p

296 n, and no changes were observed in the viral hemagglutinin, which is the receptor attachment protein.

297 Understanding site specific glycosylation of hemagglutinin will increase our knowledge about virus ev

298 3-adjuvanted vaccines (low or medium dose of hemagglutinin with AS03A or AS03B), one nonadjuvanted va

299 rog, 7.5 microg, 15 microg, and 45 microg of hemagglutinin with or without AS03 or MF59 adjuvant mixe

300 clusters of the influenza envelope protein, hemagglutinin, within the plasma membrane are hypothesiz